Table 1 Characteristics of patients included in the retrospective full cohort
Variable | Exposed (n = 1771) | Unexposed (n = 316) | Unknown (n = 168) | P-value for all | P-value for Exposed vs. Unexposed |
|---|---|---|---|---|---|
Age in years (IQR) | 37.7 (32.4–43.9) | 38.9 (33.1–46.6) | 37.7 (31.7–42.9) | 0.015 | 0.006 |
Female | 1,253 (70.8%) | 203 (64.2%) | 117 (69.6%) | 0.068 | 0.020 |
ART duration in years (IQR) | 2.4 (1.5–3.3) | 2.5 (1.6–3.5) | 2.5 (1.2–3.4) | 0.270 | 0.120 |
Prescription length in days (IQR) | 180 (65–180) | 180 (66–180) | 90 (36–180) | <0.001 | 0.846 |
Patients (%) with… | <0.001 | 0.710 | |||
1-month prescriptions | 227 (12.8%) | 43 (13.6%) | 48 (28.6%) | ||
2-month prescriptions | 282 (15.9%) | 48 (15.2%) | 24 (14.3%) | ||
3-month prescriptions | 234 (13.2%) | 35 (11.1%) | 18 (10.7%) | ||
6-month prescriptions | 1028 (58.0%) | 190 (60.1%) | 78 (46.4%) | ||
First line regimen | 1,675 (94.6%) | 295 (93.4%) | 151 (89.9%) | 0.041 | 0.383 |
Fixed dose combination | 28 (1.6%) | 5 (1.6%) | 9 (5.4%) | 0.002 | 0.999 |
No pre-program observation time | 93 (5.3%) | 22 (7.0%) | 25 (14.9%) | <0.001 | 0.220 |
Transfer out during observation | 61 (3.4%) | 8 (2.5%) | 9 (5.4%) | 0.269 | 0.507 |